Oxford Pharmascience's OXPzero reaches second trial stage
AIM-listed Oxford Pharmascience said its OXPzero pain killer drug has reached the second stage of its clinical trial.
Abaco Capital
1.50p
16:54 08/05/18
0.00%
0.00p
FTSE AIM All-Share
755.24
13:30 24/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,023.00
13:29 24/04/24
0.72%
156.92
In a statement the company said it believed preliminary data showed the ibuprofen had a clinical profile suitable for commercialisation.
The company said the drug was optimised to provide immediate release and complete drug absorption, and mask its taste.
Shares in Oxford Pharmascience were down by 0.58% at 1512 BST to 8.08p.